Ratnakar Securities Pvt. Ltd.

FREDUN PHARMACEUTICALS LTD.

NSE : NABSE : 539730ISIN CODE : INE194R01017Industry : Pharmaceuticals & DrugsHouse : Private

BSE729.359.65 (+1.34 %)

PREV CLOSE ( ) 719.70

OPEN PRICE ( ) 725.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 17638

TODAY'S LOW / HIGH ( )717.00 735.00

52 WK LOW / HIGH ( ) 635955.5

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 08-06 1987

Management Info

Daulat N Medhora - Chairman Fredun N Medhora - Managing Director

Registered Office

Address 11th Floor, Tower A,Urmi Estate 95, Ganpatrao Kadam Marg,Lower Parel (West),
Mumbai,
Maharashtra-400013

Phone 022-40318111

Email business@fredungroup.com

Website www.fredungroup.com

Registrars Details

Purva Shareregistry (India) Pvt Ltd

Gala No 9,Shiv Shakti, Industrial Estate,Sitaram Mill Comp.,J R Boricha Marg, Lower Parel [E],Mumbai

Listing : BSE

NEWS

22May Fredun Pharmaceuticals informs about
Pursuant to Regulation 29 read with Regulation 33 of SEBI (Listing Oblig..

10Apr Fredun Pharmaceuticals secures tender
Fredun Pharmaceuticals has been awarded a tender by the Tamil Nadu Medic..

03Apr Fredun Pharmaceutical informs about pr
Fredun Pharmaceutical has informed that it enclosed press release titled..

12Mar Fredun Pharmaceuticals forays into lar
Fredun Pharmaceuticals has forayed into the large animal veterinary segm..

12Mar Fredun Pharmaceuticals moves higher af
Fredun Pharmaceuticals is currently trading at Rs 695.10, up by 21.30 po..

Financials

in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	70.7199999999999	208.08
Gross Profit	80.4199999999999	282.71
Operating Profit	174.39	550.97
Net Sales	1674.08	4562.68

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 31282.70 (0.71%)	M.Cap ( in Cr)66297.82
Glaxosmithkline Phar (BSE) 3427.35 (6.32%)	M.Cap ( in Cr)58061.38
Astrazeneca Pharma I (BSE) 9487.50 (1.64%)	M.Cap ( in Cr)23718.75
Jenburkt Pharma (BSE) 1294.60 (13.22%)	M.Cap ( in Cr)571.35
Divi's Lab (BSE) 6617.45 (1.34%)	M.Cap ( in Cr)175342.00

Shareholding Pattern

	NON-INSTITUTION	49.48%
	PROMOTERS	48.93%
	FI/BANKS/INSURANCE	1.59%
	MUTUAL FUNDS/UTI	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

FREDUN PHARMACEUTICALS LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES